Artiva Biotherapeutics, Inc.
A clinical-stage biotechnology company in San Diego making off-the-shelf natural killer (NK) cell therapies, its lead candidate AlloNK designed to help antibodies destroy B-cells that drive autoimmune diseases like rheumatoid arthritis and lupus. Founded in 2019 as a spin-out of South Korea's GC Cell, it can produce thousands of doses from a single umbilical cord blood donor—a ready-made therapy that doesn't wait for a patient's own cells.
Bought 16.44M
Bought 3.52M
Bought 2.08M
Bought 833.3K
Granted 1.66M · Sold 87.7K
Bought 416.7K
Granted 338.8K · Sold 8.8K
Granted 309.5K · Sold 7.0K
Granted 220.0K
Granted 156.6K · Sold 3.1K
Granted 152.0K · Sold 7.0K
Granted 110.0K
Granted 80.0K
Granted 77.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +5 co-filersDirector, 10% owner, Director · 16 transactions | — | 34.72M | — | 16.44M | — |
| GC Cell Corp +1 co-filer10% owner · 10 transactions | — | 6.00M | — | 3.52M | — |
| Huh Yong-JunDirector · 8 transactions | — | 3.89Mas of Jul 2024 | — | 2.08M | — |
| Parmar Kush +5 co-filers10% owner · 4 transactions | — | 2.24Mas of Jul 2024 | — | 833.3K | — |
| Aslan FredChief Executive Officer, Director · 13 transactions | — | 1.54M | 1.66M | — | 87.7K |
| Adelman Robert J +4 co-filers10% owner · 4 transactions | — | 1.06Mas of Jul 2024 | — | 416.7K | — |
| Bush JenniferCOO, CLO, Compliance Officer · 9 transactions | — | 337.9K | 338.8K | — | 8.8K |
| Horan ChristopherChief Tech Operations Officer · 9 transactions | — | 293.4K | 309.5K | — | 7.0K |
| Huston Thad AllenChief Financial Officer · 1 transaction | — | 220.0K | 220.0K | — | — |
| Raymon HeatherSVP, Research and Development · 9 transactions | — | 148.2K | 156.6K | — | 3.1K |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% owner · 2 transactions | — | 145.1Kas of Jul 2024 | — | — | — |
| Banerjee SubhashisChief Medical Officer · 3 transactions | — | 145.0K | 152.0K | — | 7.0K |
| Krishnamohan NehaChief Financial Officer · 5 transactions | — | 99.4K | 110.0K | — | — |
| Graef ThorstenChief Medical Officer · 2 transactions | — | 80.0Kas of Feb 2025 | 80.0K | — | — |
| Miralles Gines DiegoPresident & Head of R&D · 1 transaction | — | 77.5K | 77.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +23.17M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.